Cagrilintide on its own
Placebo here means a dummy shot used for comparison.
In a 26-week cagrilintide study, stomach problems occurred in 41% to 63% of participants, versus 32% on placebo.
- Reported problems included feeling sick, difficulty passing stools, loose stools and reactions at the spot where the shot was given.
- The percentage differed between groups receiving different amounts of medicine in each shot.
CagriSema, the combination
CagriSema combines cagrilintide with semaglutide (Ozempic, Wegovy).
In the study called REDEFINE 1, stomach problems affected 79.6% of people on CagriSema and 39.9% on dummy shots.
- The report described most as mild to moderate and short-lived.
- Those figures belong to the combination, not cagrilintide alone.
- These study results were checked September 28, 2026. They cannot predict what will happen to one person.
The missing official drug information
The Food and Drug Administration (FDA) is the US drug regulator.
Neither cagrilintide nor CagriSema had an FDA-reviewed label—official drug-use information—as of September 28, 2026.
- That left no FDA-reviewed guidance on pregnancy, mixing medicines or who cannot use the drug at that check.
- An approved semaglutide label cannot stand in for a CagriSema label.
- Ask a clinician—the health professional assessing care—to explain what is known and what is still missing.